Literature DB >> 27178567

Increased IL-17A/IL-17F expression ratio represents the key mucosal T helper/regulatory cell-related gene signature paralleling disease activity in ulcerative colitis.

Yoichiro Iboshi1,2, Kazuhiko Nakamura3, Keita Fukaura1, Tsutomu Iwasa1, Haruei Ogino4, Yorinobu Sumida2, Eikichi Ihara1, Hirotada Akiho4, Naohiko Harada2, Makoto Nakamuta2.   

Abstract

BACKGROUND: T helper (Th) and regulatory T (Treg) cell-related cytokines are implicated in inflammatory bowel diseases, including ulcerative colitis (UC). While these cytokines are generally upregulated in inflamed mucosae, the key cytokine profile explaining disease severity has not been determined.
METHODS: The Rachmilewitz endoscopic index (REI) was assessed in 61 UC patients undergoing colonoscopy. Biopsies obtained from inflamed (REI 3-12) and noninflamed (REI 0-2) areas were analyzed by quantitative PCR for expression of mRNAs encoding cytokines and transcription factors related to Th1 (TNF-α, IFN-γ, IL-12p35, IL-12p40, and T-bet), Th2 (IL-4, IL-13, IL-33, and GATA3), Th17 (IL-17A, IL-17F, IL-21, IL-22, IL-23p19IL-6, and RORC), Th9 (IL-9, IRF4, and PU.1), and Treg (TGF-β and Foxp3). Expression patterns associated with higher REI were determined by univariate and multivariate analyses.
RESULTS: Despite general upregulation, none of these mRNAs showed univariate correlation with REI in inflamed samples. Multiple regression analysis, however, found that joint expression of IL-17A, IL-17F, IL-21, RORC, and TGF-β was significantly predictive of REI (P < 0.0002, R2 = 0.380), with major individual contributions by IL-17A (P < 0.0001) and IL-17F (P < 0.0001), which were associated with increased and decreased REI, respectively. Partial correlation analysis, validating this model, indicated differences between IL-17A and IL-17F in correlating with other targets. The IL-17A/IL-17F ratio showed a significant correlation with REI (r = 0.5124, P < 0.0001), whereas no other mRNAs were essentially predictive of REI.
CONCLUSIONS: Mucosal IL-17A/IL-17F ratio significantly correlates with endoscopic score in UC patients, accompanied by their disparate interactions with other Th/Treg-related genes.

Entities:  

Keywords:  Endoscopic score; IL-17A/IL-17F ratio; Multigene analysis; T helper subsets; Ulcerative colitis

Mesh:

Substances:

Year:  2016        PMID: 27178567     DOI: 10.1007/s00535-016-1221-1

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  46 in total

1.  Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.

Authors:  Wolfgang Hueber; Bruce E Sands; Steve Lewitzky; Marc Vandemeulebroecke; Walter Reinisch; Peter D R Higgins; Jan Wehkamp; Brian G Feagan; Michael D Yao; Marek Karczewski; Jacek Karczewski; Nicole Pezous; Stephan Bek; Gerard Bruin; Bjoern Mellgard; Claudia Berger; Marco Londei; Arthur P Bertolino; Gervais Tougas; Simon P L Travis
Journal:  Gut       Date:  2012-05-17       Impact factor: 23.059

Review 2.  The interleukin-17 cytokine family: critical players in host defence and inflammatory diseases.

Authors:  Rajita Pappu; Vladimir Ramirez-Carrozzi; Arivazhagan Sambandam
Journal:  Immunology       Date:  2011-07-04       Impact factor: 7.397

3.  TH17 cell induction and effects of IL-17A and IL-17F blockade in experimental colitis.

Authors:  Esben Gjerløff Wedebye Schmidt; Hjalte List Larsen; Nanna Ny Kristensen; Steen Seier Poulsen; Anne Marie Lynge Pedersen; Mogens Helweg Claesson; Anders Elm Pedersen
Journal:  Inflamm Bowel Dis       Date:  2013-07       Impact factor: 5.325

4.  IL-9 and its receptor are predominantly involved in the pathogenesis of UC.

Authors:  Nancy Nalleweg; Mircea Teodor Chiriac; Eva Podstawa; Christian Lehmann; Tilman T Rau; Raja Atreya; Ekaterina Krauss; Gheorghe Hundorfean; Stefan Fichtner-Feigl; Arndt Hartmann; Christoph Becker; Jonas Mudter
Journal:  Gut       Date:  2014-06-23       Impact factor: 23.059

5.  Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.

Authors:  D Rachmilewitz
Journal:  BMJ       Date:  1989-01-14

6.  Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis.

Authors:  Ivan J Fuss; Frank Heller; Monica Boirivant; Francisco Leon; Masaru Yoshida; Stefan Fichtner-Feigl; Zhiqiong Yang; Mark Exley; Atsushi Kitani; Richard S Blumberg; Peter Mannon; Warren Strober
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

7.  Interleukin-17 immunity in pediatric Crohn disease and ulcerative colitis.

Authors:  Veera Hölttä; Paula Klemetti; Harri M Salo; Antti Koivusalo; Mikko Pakarinen; Mia Westerholm-Ormio; Kaija-Leena Kolho; Outi Vaarala
Journal:  J Pediatr Gastroenterol Nutr       Date:  2013-09       Impact factor: 2.839

8.  Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta.

Authors:  K Nakamura; A Kitani; W Strober
Journal:  J Exp Med       Date:  2001-09-03       Impact factor: 14.307

9.  Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies.

Authors:  Ellen M Moran; Ronan Mullan; Jennifer McCormick; Mary Connolly; Owen Sullivan; Oliver Fitzgerald; Barry Bresnihan; Douglas J Veale; Ursula Fearon
Journal:  Arthritis Res Ther       Date:  2009-07-23       Impact factor: 5.156

10.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

View more
  7 in total

1.  Mucosal Expression of Type 2 and Type 17 Immune Response Genes Distinguishes Ulcerative Colitis From Colon-Only Crohn's Disease in Treatment-Naive Pediatric Patients.

Authors:  Michael J Rosen; Rebekah Karns; Jefferson E Vallance; Ramona Bezold; Amanda Waddell; Margaret H Collins; Yael Haberman; Phillip Minar; Robert N Baldassano; Jeffrey S Hyams; Susan S Baker; Richard Kellermayer; Joshua D Noe; Anne M Griffiths; Joel R Rosh; Wallace V Crandall; Melvin B Heyman; David R Mack; Michael D Kappelman; James Markowitz; Dedrick E Moulton; Neal S Leleiko; Thomas D Walters; Subra Kugathasan; Keith T Wilson; Simon P Hogan; Lee A Denson
Journal:  Gastroenterology       Date:  2017-01-26       Impact factor: 22.682

2.  Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation.

Authors:  Sophie Glatt; Dominique Baeten; Terry Baker; Meryn Griffiths; Lucian Ionescu; Alastair D G Lawson; Ash Maroof; Ruth Oliver; Serghei Popa; Foteini Strimenopoulou; Pavan Vajjah; Mark I L Watling; Nataliya Yeremenko; Pierre Miossec; Stevan Shaw
Journal:  Ann Rheum Dis       Date:  2017-12-23       Impact factor: 19.103

Review 3.  The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond.

Authors:  Nicolo Costantino Brembilla; Luisa Senra; Wolf-Henning Boehncke
Journal:  Front Immunol       Date:  2018-08-02       Impact factor: 7.561

4.  Uncovering the mechanism of Ge-Gen-Qin-Lian decoction for treating ulcerative colitis based on network pharmacology and molecular docking verification.

Authors:  Lin Xu; Jiaqi Zhang; Yifan Wang; Zedan Zhang; Fengyun Wang; Xudong Tang
Journal:  Biosci Rep       Date:  2021-02-26       Impact factor: 3.840

5.  Analysis of the Efficacy and Pharmacological Mechanisms of Action of Zhenren Yangzang Decoction on Ulcerative Colitis Using Meta-Analysis and Network Pharmacology.

Authors:  Guosheng Xing; Yufeng Zhang; Xinlin Wu; Hua Wang; Yan Liu; Zhen Zhang; Mingxing Hou; Haibing Hua
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-28       Impact factor: 2.629

Review 6.  Targeting the Interleukin-23/Interleukin-17 Inflammatory Pathway: Successes and Failures in the Treatment of Axial Spondyloarthritis.

Authors:  Runsheng Wang; Walter P Maksymowych
Journal:  Front Immunol       Date:  2021-09-03       Impact factor: 7.561

Review 7.  Dissecting the Heterogeneity in T-Cell Mediated Inflammation in IBD.

Authors:  Irma Tindemans; Maria E Joosse; Janneke N Samsom
Journal:  Cells       Date:  2020-01-02       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.